Canakinumab

Generic Name: Canakinumab

Brand Names: Ilaris

Drug Type: Biotech

Chemical Formula: -

CAS Number: 914613-48-2

Unique Ingredient Identifier: 37CQ2C7X93

Background: Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain ...

Indication: Canakinumab is indicated for the treatment of periodic fever syndromes in specific patient populations. In patients ≥4 years of age, canakinumab is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). In adult and pediatric patients, canakinum...

Associated Conditions: Adult Onset Still's Disease, Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS), Familial Mediterranean Fever (FMF ), Gout Flares, Mevalonate Kinase Deficiency, Muckle-Wells Syndrome (MWS), Systemic Juvenile Idiopathic Arthritis (SJIA), Tumour necrosis factor receptor-associated periodic syndrome

Associated Therapies: -

Clinical Trials

Canakinumab in Patients With COVID-19 and Type 2 Diabetes

Phase 3

Completed

Conditions: Coronavirus Infection
Diabetes Mellitus, Type 2

Interventions: Drug: Canakinumab
Drug: Placebo

First Posted Date: 2020-08-12

Last Posted Date: 2021-09-08

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 116

Registration Number: NCT04510493

Locations: 🇨🇭
University Hospital Bern, Bern, Switzerland
🇨🇭
University Hospital Zürich, Zürich, Switzerland
🇨🇭
University Medical Clinic Aarau, Aarau, Switzerland

and more 6 locations

Canakinumab MAP in COVID-19 Pneumonia With CRS

Conditions: Cytokine Release Syndrome in COVID-19-induced Pneumonia

First Posted Date: 2020-07-20

Last Posted Date: 2021-02-03

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04476706

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia

Phase 3

Completed

Conditions: Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia

Interventions: Drug: Placebo
Drug: Canakinumab

First Posted Date: 2020-04-27

Last Posted Date: 2022-01-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 454

Registration Number: NCT04362813

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients with Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Phase 2

Recruiting

Conditions: Myelodysplastic Syndrome
Refractory Myelodysplastic Syndrome
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Refractory Chronic Myelomonocytic Leukemia

Interventions: Biological: Canakinumab

First Posted Date: 2020-01-23

Last Posted Date: 2024-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 76

Registration Number: NCT04239157

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma

Early Phase 1

Recruiting

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Spartalizumab
Drug: Canakinumab

First Posted Date: 2019-07-22

Last Posted Date: 2024-07-09

Lead Sponsor: Columbia University

Target Recruit Count: 14

Registration Number: NCT04028245

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Canakinumab
Drug: Pembrolizumab

First Posted Date: 2019-05-30

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 88

Registration Number: NCT03968419

Locations: 🇺🇸
University of Kansas Medical Center Neurology Dept., Kansas City, Kansas, United States
🇺🇸
Methodist Hospital / Methodist Cancer Center, Houston, Texas, United States
🇺🇸
UCLA Oncology Hematology, La Jolla, California, United States

and more 2 locations

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Phase 3

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: canakinumab
Drug: canakinumab-matching placebo
Drug: pembrolizumab
Drug: carboplatin
Drug: cisplatin
Drug: pemetrexed
Drug: paclitaxel
Drug: nab-paclitaxel

First Posted Date: 2018-08-15

Last Posted Date: 2024-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 673

Registration Number: NCT03631199

Locations: 🇺🇸
Pacific Shores Medical Group ., Long Beach, California, United States
🇺🇸
USC Kenneth Norris Comprehensive Cancer Center ., Los Angeles, California, United States
🇺🇸
Advent Health Cancer Institute, Orlando, Florida, United States

and more 2 locations

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

Phase 3

Terminated

Conditions: Non-Small-Cell Lung

Interventions: Drug: Canakinumab
Drug: Docetaxel
Other: Placebo

First Posted Date: 2018-08-13

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 245

Registration Number: NCT03626545

Locations: 🇺🇸
University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
🇺🇸
Montefiore Medical Center Albert Einstein College of Med, Bronx, New York, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 4 locations

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: PDR001
Drug: LAG525
Drug: ACZ885
Drug: LEE011
Drug: INC280

First Posted Date: 2018-04-02

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 196

Registration Number: NCT03484923

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital Massachusetts Gen. Hospital CC, Boston, Massachusetts, United States

and more 4 locations

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Canakinumab

First Posted Date: 2018-02-27

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1382

Registration Number: NCT03447769

Locations: 🇺🇸
Cancer Center of Kansas Dept.ofCancerCtr.ofKansas, Wichita, Kansas, United States
🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸
Advanced Medical Specialties Drug Ship - 2, Miami, Florida, United States

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy